Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

@inproceedings{Adelman2012EvaluationOL,
  title={Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study},
  author={Daphne T. Adelman and Andrea Burgess and Philippa R Davies},
  booktitle={Medical devices},
  year={2012}
}
The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
13 Citations
12 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Sandostatin LAR: mixing

  • AG Novartis
  • Available from: http:// www.sandostatin.com/about…
  • 2012

Ease of administration of somatostatin analogs, octreotide LAR versus lanreotide [abstract

  • K Schweinsberg, S Smith, LS. Kirshner
  • Endocr Rev. 2011;32(03_Meeting Abstracts):P1–P451
  • 2011

Similar Papers

Loading similar papers…